secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001140361-25-005571
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech announces Versamune® HPV ctDNA results: 100% clearance vs 50% CRT alone; Phase 3 HNSCC trial planned Q1 2025
--------------------------------------------------------------------------------

- Versamune® HPV + CRT achieved 100% HPV16 ctDNA clearance at 3-4 months vs 50% with CRT alone in cervical cancer.
- Undetectable ctDNA at 3-4 months linked to 93% 2-year recurrence-free survival vs 30% with detectable ctDNA.
- Phase 3 VERSATILE-003 trial in HPV16-positive HNSCC to be initiated in Q1 2025.
- Plans to discuss accelerated regulatory pathway (e.g., Breakthrough Therapy) with FDA based on ctDNA-survival correlation.
- Median follow-up 23 months; 100% 36-month OS in patients receiving 5 doses of Versamune® HPV + CRT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125005571/0001140361-25-005571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125005571/ef20044142_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer